Coloplast As Sp/Adr (CLPBY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Coloplast AS Q1 2024-25 Earnings Release Conference Call. I'm Valentina, the chorus call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing SA and 1 on your telephone. For operator assistance, please press SA and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Christian Willemsen, President and CEO. Please go ahead. Good morning and welcome to our Q1 2425 conference call. I'm Christian Willemsen, the CEO of Coloplast, and I'm joined by our CFO, Anas Laninskoglu, and our investor relations team. We'll start with a short presentation by Anderson, myself, and then open up for questions as we usually do. Please turn to slide number three. We delivered 8% organic growth and a reported EBIT margin before special items of 27%, which was in line with our expectations. Adjusted return on invested capital after tax and before special items was 15% on par with last year. Let me start today's call with a few highlights. On the 14th of November, 2024, the final local coverage determination policy for skin substitutes was announced. Kerasys was one of the few products that was added back to the final list of covered products as a result of the strong clinical evidence backing the efficacy of the Fishkin technology. Following a freeze of all regulatory guidance not yet in effect by the new U.S. administration, the implementation date of the final LCD policy has been moved by two months to the 13th of April, 2025. CareAssist's products are currently covered and will remain covered once the final LCD...